Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August
Editas Medicine (NASDAQ: EDIT) is researching the use of gene editing to treat disease. After the company updated investors on its progress on Aug. 9, shares soared 18.8% last month, according to S&P Global Market Intelligence.
Editas Medicine is conducting preclinical-stage research on a gene-editing technique called CRISPR-Cas9, which it licensed from the Broad Institute (affiliated with Harvard and the Massachusetts Institute of Technology).
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
